Celerion, a global leader in early clinical research, announced today that it has received full reaccreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for a period of five years. The Council on Accreditation of AAHRPP conducted a thorough review, recognizing Celerion as the only U.S.-headquartered contract research organization (CRO) to hold this distinguished distinction. This reaccreditation underscores the company’s unwavering commitment to ethical standards, participant protection, and excellence in clinical research.
AAHRPP accreditation is widely regarded as a hallmark of quality in the research industry. It reflects rigorous adherence to policies, procedures, and practices that safeguard participants, while fostering a culture of continuous improvement. By achieving reaccreditation, Celerion reinforces its position as an industry leader capable of conducting complex clinical studies in a safe, compliant, and ethical manner.
“This milestone represents the hard work and dedication of our entire team,” said Phil Bach, Executive Vice President of Global Clinical Research at Celerion. “We are deeply committed to upholding participant safety and the highest ethical standards in our research. Earning AAHRPP reaccreditation for five years reflects our steadfast focus on setting the benchmark for clinical research excellence and integrity. We are honored to receive this recognition and remain focused on making meaningful contributions to the field of clinical development.”
Rigorous Accreditation Process
The AAHRPP reaccreditation process is among the most comprehensive in the industry. It involves detailed evaluations of organizational policies, operational practices, and ongoing improvement efforts related to human research protection. Achieving this accreditation demonstrates Celerion’s ability to manage sophisticated clinical programs while maintaining participant welfare as a top priority, ensuring ethical and compliant execution at every stage of a study.
Celerion’s reaccreditation emphasizes the company’s commitment to:
- Protecting participants in clinical research
- Maintaining regulatory compliance across global studies
- Promoting ethical practices throughout trial design and execution
- Supporting continuous learning and improvement in research practices
Decades of Clinical Research Leadership
With more than 50 years of experience, Celerion has established a global reputation for innovation and operational excellence in clinical trials. The company provides end-to-end solutions for early-phase studies, including first-in-human trials, pharmacokinetics, and biomarker assessments, and has consistently prioritized participant safety, data integrity, and regulatory adherence.
The reaccreditation validates Celerion’s long-standing dedication to regulatory and ethical excellence, positioning it as a trusted partner for sponsors seeking to conduct high-quality, safe, and compliant clinical research. It also serves as a benchmark for industry best practices, demonstrating that the company’s standards exceed conventional requirements.
“AAHRPP reaccreditation highlights the strength of our operational framework and reinforces our responsibility to participants, sponsors, and the broader clinical research community,” added Bach. “Our team’s expertise and rigorous processes ensure that every study we conduct is guided by integrity, transparency, and respect for human research protection.”
Global Impact and Future Outlook
Celerion’s reaccreditation supports its mission to advance scientific innovation while maintaining the highest ethical standards. As clinical research becomes increasingly complex, this recognition demonstrates the company’s ability to navigate regulatory requirements across multiple regions and deliver results with integrity.
Sponsors partnering with Celerion benefit from:
- Confidence in ethical research practices
- Adherence to international standards for participant protection
- Expertise in managing early-phase clinical trials efficiently and safely
- Access to a CRO recognized for continuous improvement and quality
The five-year AAHRPP reaccreditation not only cements Celerion’s credibility but also serves as a strong signal to the industry that the company is committed to leading ethical and responsible clinical research.
Celerion continues to build on this foundation, ensuring that clinical innovation, participant safety, and regulatory compliance remain central to its mission. With this reaccreditation, the company is poised to support sponsors globally, advancing life-changing therapies while maintaining the highest standards of ethical research practices.
This achievement reflects Celerion’s dedication to excellence, reinforcing its reputation as a trusted partner in the clinical research ecosystem and setting the stage for continued leadership in ethical, high-quality early-phase clinical studies.
